指南与共识支持与姑息治疗

成人癌症患者使用大麻与大麻素:ASCO指南

Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline.
指南 / 共识 · J Clin Oncol · 2024-03-13

ASCO召集专家小组,系统检索截至2023年1月27日的文献,纳入13篇系统综述和5项原始研究(4项随机对照试验和1项队列研究),制定成人癌症患者医疗使用大麻和大麻素的推荐。证据总体确定性低或极低;指南建议除非在临床试验中,否则不推荐将大麻或大麻素作为抗癌治疗;作为止吐方案的辅助可能改善难治性化疗所致恶心呕吐。

要点

  • 除非在临床试验中,否则不推荐将大麻或大麻素作为抗癌治疗。
  • 大麻和/或大麻素加入符合指南的止吐方案后,可能改善难治性化疗所致恶心呕吐。
  • 大麻和/或大麻素能否改善其他支持治疗结局仍不确定。

核心结论

  • 成人癌症患者获取和使用大麻和/或大麻素已超出支持其临床使用的科学证据。
  • 除非在临床试验中,否则不推荐将大麻或大麻素作为抗癌治疗。
  • 大麻和/或大麻素加入符合指南的止吐方案后可能改善难治性化疗所致恶心呕吐。
  • 大麻和/或大麻素能否改善其他支持治疗结局仍不确定。

研究设计与样本

  • ASCO召集专家小组,系统检索PubMed和Cochrane Library从建库至2023年1月27日的文献,纳入13篇系统综述和5项原始研究(4项随机对照试验和1项队列研究),审查证据并制定推荐。

主要发现

  • 证据基础包括13篇系统综述和5项原始研究(4项随机对照试验和1项队列研究)。
  • 大多数结局的证据确定性为低或极低。

关键数值与推荐

  • 除非在临床试验中,否则不推荐将大麻或大麻素作为抗癌治疗。
  • 大麻和/或大麻素加入符合指南的止吐方案后可能改善难治性化疗所致恶心呕吐。
  • 大麻和/或大麻素能否改善其他支持治疗结局仍不确定。

临床怎么用

  • 指南提供临床医生与成人癌症患者就大麻和/或大麻素使用进行开放、非评判性沟通的策略。
  • 临床医生应推荐不将大麻或大麻素作为抗癌治疗,除非在临床试验中。
  • 大麻和/或大麻素加入符合指南的止吐方案后可能用于改善难治性化疗所致恶心呕吐。

局限性

  • 大多数结局的证据确定性为低或极低。
  • 指南强调亟需更多大麻和/或大麻素研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To guide clinicians, adults with cancer, caregivers, researchers, and oncology institutions on the medical use of cannabis and cannabinoids, including synthetic cannabinoids and herbal cannabis derivatives; single, purified cannabinoids; combinations of cannabis ingredients; and full-spectrum cannabis. METHODS: A systematic literature review identified systematic reviews, randomized controlled trials (RCTs), and cohort studies on the efficacy and safety of cannabis and cannabinoids when used by adults with cancer. Outcomes of interest included antineoplastic effects, cancer treatment toxicity, symptoms, and quality of life. PubMed and the Cochrane Library were searched from database inception to January 27, 2023. ASCO convened an Expert Panel to review the evidence and formulate recommendations. RESULTS: The evidence base consisted of 13 systematic reviews and five additional primary studies (four RCTs and one cohort study). The certainty of evidence for most outcomes was low or very low. RECOMMENDATIONS: Cannabis and/or cannabinoid access and use by adults with cancer has outpaced the science supporting their clinical use. This guideline provides strategies for open, nonjudgmental communication between clinicians and adults with cancer about the use of cannabis and/or cannabinoids. Clinicians should recommend against using cannabis or cannabinoids as a cancer-directed treatment unless within the context of a clinical trial. Cannabis and/or cannabinoids may improve refractory, chemotherapy-induced nausea and vomiting when added to guideline-concordant antiemetic regimens. Whether cannabis and/or cannabinoids can improve other supportive care outcomes remains uncertain. This guideline also highlights the critical need for more cannabis and/or cannabinoid research.Additional information is available at www.asco.org/supportive-care-guidelines.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Braun IM, Bohlke K, Abrams DI, et al. Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline. J Clin Oncol. 2024. PMID: 38478773. doi:10.1200/JCO.23.02596

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。